Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes by utilizing advanced adaptive closed-loop algorithms. The company's flagship product is the iLet Bionic Pancreas, the first FDA-cleared insulin delivery device that autonomously determines every insulin dose without requiring carbohydrate counting, designed for type 1 diabetes patients ages 6 and older.
Public Company
Beta Bionics is publicly traded
IPO'd on January 30, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under BBNX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
370–420
Total Funding
$165M
3 rounds
Funding
Total raised $165M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series E
Date
November 2024
Amount
$60M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 2024 | Series E | $60M | — | Not disclosed |
| August 2023 | Series D | $100M | — | Not disclosed |
| 2015 | Seed | $5M | — | Novo Nordisk, Eli Lilly |
Prominent Investors
Leadership
Sean Saint
Chief Executive Officer & Board Member
Stephen Feider
Chief Financial Officer
Steven Russell
Chief Medical Officer
Mike Mensinger
Chief Product Officer
Mark Hopman
Chief Commercial Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Medtronic
Large medtech company offering MiniMed insulin pump systems and competing in automated insulin delivery space with next-gen patch pump technology
Tandem Diabetes Care
Insulin pump manufacturer offering t:slim X3 tubed pump and developing Sigi patch pump for automated insulin delivery
Insulet
Developer of Omnipod, the only fully disposable, tubeless insulin pump system in the market
Novo Nordisk
Pharmaceutical and medical device company with insulin and diabetes management solutions
Eli Lilly
Pharmaceutical company providing insulin therapies and diabetes medications
Beta Bionics Investment FAQ
Beta Bionics FAQ
Yes, Beta Bionics is publicly traded under the ticker symbol BBNX on the NASDAQ. The company went public in January 30, 2025.
Beta Bionics trades under the ticker symbol BBNX on the NASDAQ. It began trading in January 30, 2025.
Beta Bionics (BBNX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker BBNX to place an order.
Beta Bionics went public in January 30, 2025 via ipo. Beta Bionics completed its initial public offering on January 31, 2025, raising $234.6M in gross proceeds (including full exercise of underwriters' option). The company trades on NASDAQ under ticker symbol BBNX. Shares began trading on January 30, 2025 at $22 per share (29% opening gain from $17 IPO price). IPO was led by BofA Securities, Piper Sandler, and Leerink Partners.
Beta Bionics raised $165M across 3 disclosed funding rounds prior to its public listing.
Beta Bionics is headquartered in Irvine, CA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.